The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
SOUTH SAN FRANCISCO, Calif. & HEIDELBERG, Germany, June 03, 2026--Mission Bio, a leader in single-cell multiomics, jointly ...
Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of ...
An experimental treatment for spinal cord injuries has ignited a frenzy in Brazil, drawing patients from as far off as Mexico ...
European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.
A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A ...
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a ...
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong ...
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered ...
REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-concept in ACC. In this study, pharmacokinetic and pharmacodynamic analyses conirmed robust compound exposure in blood and target ...
Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results